Get the Stockscreener App
1.23
6.03%
0.07
After Hours:
1.09
-0.14
-11.38%
Scinai Immunotherapeutics Ltd Adr stock is traded at $1.23, with a volume of 63.59M.
It is up +6.03% in the last 24 hours and down -25.90% over the past month.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.
See More
Previous Close:
$1.16
Open:
$1.56
24h Volume:
63.59M
Relative Volume:
9.93
Market Cap:
$833.42K
Revenue:
$1.22M
Net Income/Loss:
$-3.26M
P/E Ratio:
-0.2001
EPS:
-6.1455
Net Cash Flow:
$-6.38M
1W Performance:
+0.82%
1M Performance:
-25.90%
6M Performance:
-79.22%
1Y Performance:
-90.96%
1-Day Range:
$1.1401
$1.76
1-Week Range:
$1.06
$1.76
52-Week Range:
$1.06
$15.65
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Company Profile
Name
Scinai Immunotherapeutics Ltd Adr
Sector
Industry
Phone
972-8-9302529
Address
JERUSALEM BIOPARK, 2ND FLOOR, JERUSALEM
Compare SCNI vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCNI
Scinai Immunotherapeutics Ltd Adr
|
1.23 | 833.42K | 1.22M | -3.26M | -6.38M | -6.1455 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Latest News
Scinai files prospectus for resale of 2.7 million ADSs - scanx.trade
Scinai Immunotherapeutics regains Nasdaq compli... - Pluang
Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement - PR Newswire
Nasdaq closes Scinai's $1 stock-price matter after 19 business days - Stock Titan
Scinai Immunotherapeutics (SCNI) Edges Higher to $1.71 as Biotech Micro-Cap Holds Key SupportWave Extension - dars.gov.et
Scinai Immunotherapeutics refocuses capital on NanoAb platform and CDMO business - TipRanks
Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business - Barchart.com
Scinai (NASDAQ: SCNI) updates $15M equity deal that could dilute investors - Stock Titan
Earnings call transcript: Scinai posts H1 2026 revenue growth as losses persist - Investing.com Nigeria
Earnings call transcript: Scinai posts H1 2026 revenue growth as losses persist - Investing.com
Scinai reports H1 2026 results, announces U.S. customer expansion - Investing.com India
Scinai Immunotherapeutics (NASDAQ: SCNI): Why Is A recent reverse share split that reset the chart structure in Focus Now? - Kalkine Media
Scinai (SCNI) Technicals: Ends Down by 5.59% at $3.04 in the Current Update; Levels: $2.89 and $3.19 Define the Nearby Reference Levels in the Latest ReadingFactor Valuation - careplusvn.com
Scinai (SCNI) Technicals: Ends Down by 5.59% at $3.04 in the Current Update; Levels: $2.89 and $3.19 Define the Nearby Reference Levels in the Latest ReadingTriangle Correction - dars.gov.et
Scinai reports H1 2026 results, announces U.S. customer expansion - Investing.com
Scinai (SCNI) Technicals: Ends Down by 5.59% at $3.04 in the Current Update; Levels: $2.89 and $3.19 Define the Nearby Reference Levels in the Latest ReadingOversold Bounce Ideas - dars.gov.et
Scinai (SCNI) Earnings Update: EPS Beats Its Estimate in the Latest Session; Price Move - dars.gov.et
What Could Scinai Immunotherapeutics (NASDAQ:SCNI) Reveal Today About Its Next Operating Milestones? - Kalkine Media
Scinai Immunotherapeutics Sets 1-for-10 ADS Ratio Change to Support Nasdaq Compliance - The Globe and Mail
Scinai Immunotherapeutics Sets 1-for-10 ADS Ratio Change to Support Nasdaq Compliance - TipRanks
Scinai (NASDAQ: SCNI) turns to reverse split to chase Nasdaq $1 minimum - Stock Titan
Scinai (SCNI) Latest Results Brief: EPS Exceeds Its Estimate at the Close; Post-Earnings Trading: Shares Finish 2.44% Up on the DayDividend Increase Stocks - dars.gov.et
Scinai (SCNI) Latest Results Brief: EPS Exceeds Its Estimate at the Close; Post-Earnings Trading: Shares Finish 2.44% Up on the DayEarnings Miss Streak - dars.gov.et
Scinai (SCNI) Latest Results Brief: EPS Exceeds Its Estimate at the Close; Post-Earnings Trading: Shares Finish 2.44% Up on the DayAnalyst Coverage Count - dars.gov.et
Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration - Barchart.com
Scinai Immunotherapeutics (SCNI) Slips 6.6% as Shares Test Key Support at $0.25Volatility Stop - careplusvn.com
Scinai Immunotherapeutics (SCNI) Slips 2.41% as Stock Hovers Near Key Support at $0.24Wedge Breakout - dars.gov.et
Scinai Immunotherapeutics (SCNI) Edges Higher Amid Tight Trading RangeCharm Flow - careplusvn.com
Scinai Immunotherapeutics (SCNI) Edges Higher Amid Tight Trading RangeGap Fill Strategy - dars.gov.et
Scinai Immunotherapeutics Ltd. (SCNI) Edges Higher in Tight Range as Support and Resistance Levels HardenRisk Reward Setups - careplusvn.com
Scinai Immunotherapeutics Q4 2023 Earnings: EPS Surprises to the Upside Despite No Revenue; Stock DeclinesShare Dilution Risk - careplusvn.com
Scinai Immunotherapeutics Q4 2023 Earnings: EPS Surprises to the Upside Despite No Revenue; Stock Declines - dars.gov.et
Scinai Immunotherapeutics Q4 2023 Earnings: EPS Surprises to the Upside Despite No Revenue; Stock DeclinesLow Growth Earnings - dars.gov.et
SCNIScinai Immunotherapeutics Ltd ADR Latest SEC Filings - Finviz
SCNIScinai Immunotherapeutics Ltd ADR Options - Finviz
Scinai Immunotherapeutics Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:SCNI) - TradingView
Price to sales forward of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView
Enterprise value to revenue forward of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView
Enterprise value to EBITDA forward of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView
Enterprise value to EBIT forward of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView
Why Scinai Immunotherapeutics stock is skyrocketing 90% higher today - MSN
Why Scinai Immunotherapeutics stock is skyrocketing 90% higher today - MSN
Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives - Barchart.com
Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives - Sahm
SCNI - Finviz
SCNI Technical Analysis | Trend, Signals & Chart Patterns | SCINAI IMMUNOTHERAPEUTICS LT (NASDAQ:SCNI) - ChartMill
Scinai appoints Eilon Elmalem as Yavne CDMO facility head - Investing.com
Scinai appoints Eilon Elmalem as Yavne CDMO facility head By Investing.com - Investing.com India
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility - Barchart.com
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe - Sahm
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):